Sujata M. Bhavnani

Sujata M. Bhavnani publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where Sujata M. Bhavnani sits on this spectrum.

Sujata M. Bhavnani D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where Sujata M. Bhavnani sits on this spectrum.

Best Publications

• Pharmacokinetics-Pharmacodynamics of Antimicrobial Therapy: It's Not Just for Mice Anymore

  Paul G. Ambrose;Sujata M. Bhavnani;Christopher M. Rubino;Arnold Louie

  819
  Citations

• Pharmacodynamic Evaluation of Factors Associated with the Development of Bacterial Resistance in Acutely Ill Patients during Therapy

  Jennifer K. Thomas;Alan Forrest;Sujata M. Bhavnani;Judith M. Hyatt

  699
  Citations

• Voriconazole Therapeutic Drug Monitoring

  J. Smith;N. Safdar;V. Knasinski;W. Simmons

  504
  Citations

• Back to the Future: Using Aminoglycosides Again and How to Dose Them Optimally

  George L Drusano;Paul G Ambrose;Sujata M Bhavnani;Joseph S Bertino

  297
  Citations

• Daptomycin Exposure and the Probability of Elevations in the Creatine Phosphokinase Level: Data from a Randomized Trial of Patients with Bacteremia and Endocarditis

  Unknown

  295
  Citations

• A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia.

  Sujata M. Bhavnani;Julie A. Drake;Alan Forrest;June A. Deinhart

  257
  Citations

• Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus

  Pamela A. Moise;Alan Forrest;Sujata M. Bhavnani;Mary C. Birmingham

  221
  Citations

• Association of Fluconazole Pharmacodynamics with Mortality in Patients with Candidemia

  John W. Baddley;Mukesh Patel;Sujata M. Bhavnani;Stephen A. Moser

  215
  Citations

• Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations.

  Tawanda Gumbo;Arnold Louie;Weiguo Liu;David Brown

  195
  Citations

• Pharmacokinetic-Pharmacodynamic Considerations in the Design of Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia Studies: Look before You Leap!

  Paul G. Ambrose;Sujata M. Bhavnani;Evelyn J. Ellis-Grosse;George L. Drusano

  184
  Citations

• Background and rationale for revised clinical and laboratory standards institute interpretive criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam.

  Michael N Dudley;Paul G Ambrose;Sujata M Bhavnani;William A Craig

  183
  Citations

• Randomized Pharmacokinetic and Pharmacodynamic Comparison of Fluoroquinolones for Tuberculous Meningitis

  Guy E. Thwaites;Guy E. Thwaites;Sujata M. Bhavnani;Tran Thi Hong Chau;Jeffrey P. Hammel

  176
  Citations

• Use of Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Support Phase 2 and 3 Dosing Strategies for Doripenem

  Unknown

  158
  Citations

• Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model.

  Brian VanScoy;Rodrigo E. Mendes;Anthony M. Nicasio;Mariana Castanheira

  144
  Citations

• Pharmacokinetics-Pharmacodynamics of Cefepime and Piperacillin- Tazobactam against Escherichia coli and Klebsiella pneumoniae Strains Producing Extended-Spectrum β-Lactamases: Report from the ARREST Program

  P. G. Ambrose;S. M. Bhavnani;R. N. Jones

  140
  Citations

• Isoniazid's Bactericidal Activity Ceases because of the Emergence of Resistance, Not Depletion of Mycobacterium tuberculosis in the Log Phase of Growth

  Tawanda Gumbo;Arnold Louie;Weiguo Liu;Paul G. Ambrose

  139
  Citations

• New agents for Gram-positive bacteria

  Unknown

  136
  Citations

• Pharmacokinetic and Pharmacodynamic Evaluation of Liposomal Amikacin for Inhalation in Cystic Fibrosis Patients with Chronic Pseudomonal Infection

  Ólanrewaju O. Okusanya;Sujata M. Bhavnani;Jeffrey Hammel;Predrag Minic

  128
  Citations

• Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults.

  C.M. Rubino;S.M. Bhavnani;P.G. Ambrose;A. Forrest

  126
  Citations

• Use of Pharmacokinetic-Pharmacodynamic Analyses to Optimize Therapy with the Systemic Antifungal, Micafungin, for Invasive Candidiasis or Candidemia

  David Andes;Paul G. Ambrose;Jeffrey P. Hammel;Scott A. Van Wart

  123
  Citations